Download full-text PDF |
Source |
---|
Arrhythm Electrophysiol Rev
November 2014
Georges Pompidou European Hospital and Paris Descartes University, Paris, France.
Stroke prevention is central to the management of patients with atrial fibrillation (AF). Vitamin K antagonists (VKAs) are the established and long-standing option for stroke prevention therapy in patients with AF. However, non-VKA oral anticoagulants (NOACs) have recently been developed and demonstrated non-inferior efficacy vs VKA treatment, with fewer limitations in clinical practice and with reduced risks of major bleeding.
View Article and Find Full Text PDFPacing Clin Electrophysiol
January 2005
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!